You can buy or sell AGLE and other stocks, options, ETFs, and crypto commission-free!
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. Read More The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
52 Week High
52 Week Low
— per share
Expected May 5, Pre-Market